Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 55 Show results per page	View Search Criteria \| Help With Results

Last Modified: 9/1/1995


1.		Phase II/III Randomized Study of CD8+ TIL/IL-2 for Metastatic Renal Cell Carcinoma (Summary Last Modified 09/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				AIS-1061-9320 NCI-V95-0689

Last Modified: 11/30/2006


2.		Phase I/II Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T-Cells in Patients With Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 to 75				NCI				FHCRC-1017.01 NCI-V96-0920, NCT00002786

Last Modified: 8/21/2007


3.		Phase I/II Study of Interferon Alfa, Interleukin-2, and In Vivo-Primed Tumor Infiltrating Lymphocytes Isolated from Metastatic Sites or Regional Lymph Nodes in Patients with Metastatic Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				over 18				Other				UCLA-HSPC-9502083 NCI-V96-0944

Last Modified: 12/6/2007


4.		Phase I/II Chemoimmunotherapy with IL-2/CY, plus Tumor Infiltrating Lymphocytes in Selected Patients and alpha-Interferon in Some Patients, in Treatment of Advanced Refractory Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				any age				NCI				NCI-86-C-183E NCI-T86-0225N, T86-0225

Last Modified: 7/1/1989


5.		Phase I/II Study of rIL-2/TIL plus CTX in Patients with Metastatic Carcinoma, Sarcoma, or Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over								NBSG-8720 NCI-V88-0615

Last Modified: 8/1/1993


6.		Phase I/II Study of In Vivo-Primed TIL in Combination with IFN-A/IL-2 in Patients with Metastatic Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over								UCLA-9102071 UCLA-UO-91-1, NCI-B91-0006, B91-0006

Last Modified: 12/1/1992


7.		Phase I/II Study of TIL/IL-2 in Patients with Advanced Melanoma (Summary Last Modified 12/92)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				16 and over				NCI				PCI-9038 NCI-T91-0133O, T91-0133

Last Modified: 7/1/1993


8.		Phase I/II Study of In Vitro-Expanded CD8(+) TIL in Combination with IL-2 or IL-2/IFN-A in Patients with Metastatic Renal Cell Carcinoma (Summary Last Modified 07/93)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over								UCLA-9102052 NCI-V91-0217

Last Modified: 1/1/1993


9.		Phase II Trial of TIL/IFN-A/IL-2 in Patients with Advanced Cancer (Summary Last Modified 01/93)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over								NBSG-9201 NCI-V92-0156

Last Modified: 10/17/2003 First Published: 10/1/2002


10.		Phase I/II Randomized Study of High-Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation Followed By Immunotherapy With Costimulated Autologous T Cells Plus Pneumococcal Conjugate Vaccine in Patients With Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Supportive care, Treatment				Closed				18 to 80				Other				MSGCC-0065 UPCC-6401, NCI-V02-1709, NCT00046852

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute